Workflow
Marinus Pharmaceuticals(MRNS)
icon
Search documents
The Gross Law Firm Notifies Marinus Pharmaceuticals, Inc. Investors of a Class Action Lawsuit and Upcoming Deadline - MRNS
Prnewswire· 2024-07-25 09:45
Shareholders who purchased shares of MRNS during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointment. Appointment as lead plaintiff is not required to partake in any recovery. https://securitiesclasslaw.com/securities/marinus-pharmaceuticals-inc-loss-submission-form/? id=91974&from=4 ALLEGATIONS: The complaint alleges that during the class period, Defendants issued materially false and/or misleading statements and/or failed to disclose that: (1) defendant ...
MRNS Investors Have Opportunity to Lead Marinus Pharmaceuticals, Inc. Securities Lawsuit Filed by the Schall Law Firm
Prnewswire· 2024-07-24 15:15
Group 1 - A class action lawsuit has been filed against Marinus Pharmaceuticals, Inc. for violations of the Securities Exchange Act of 1934 [5] - The lawsuit alleges that Marinus made false and misleading statements regarding the risks associated with its RAISE trial, specifically underestimating the potential for failure [7] - The company failed to disclose that not meeting early stopping criteria in the RAISE trial could halt the separate Phase 3 RAISE II trial, leading to materially misleading public statements [7] Group 2 - Investors who purchased Marinus securities between March 17, 2021, and May 7, 2024, are encouraged to contact the Schall Law Firm before August 5, 2024, to discuss their rights [2] - The class has not yet been certified, meaning that until certification occurs, investors are not represented by an attorney [3] - The Schall Law Firm specializes in securities class action lawsuits and represents investors globally [8]
Faruqi & Faruqi LLP Reminds Shareholders of a Lead Plaintiff Deadline on August 5, 2024 in Marinus Lawsuit
Prnewswire· 2024-07-19 13:50
NEW YORK, July 19, 2024 /PRNewswire/ -- Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against Marinus Pharmaceuticals, Inc. ("Marinus" or the "Company") (NASDAQ: MRNS) and reminds investors of the August 5, 2024 deadline to seek the role of lead plaintiff in a federal securities class action that has been filed against the Company. As detailed below, the complaint alleges that the Company and its executives violated federal securities laws by making false an ...
Marinus Pharmaceuticals, Inc. Sued for Securities Law Violations - Investors Should Contact The Gross Law Firm Before August 5, 2024 to Discuss Your Rights - MRNS
Prnewswire· 2024-07-17 09:45
Shareholders who purchased shares of MRNS during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointment. Appointment as lead plaintiff is not required to partake in any recovery. https://securitiesclasslaw.com/securities/marinus-pharmaceuticals-inc-loss-submission-form/? id=90884&from=4 ALLEGATIONS: The complaint alleges that during the class period, Defendants issued materially false and/or misleading statements and/or failed to disclose that: (1) defendant ...
Levi & Korsinsky Notifies Marinus Pharmaceuticals, Inc. Investors of a Class Action Lawsuit and Upcoming Deadline – MRNS
GlobeNewswire News Room· 2024-07-16 16:36
NEW YORK, July 16, 2024 (GLOBE NEWSWIRE) -- Levi & Korsinsky, LLP notifies investors in Marinus Pharmaceuticals, Inc. ("Marinus" or the "Company") (NASDAQ: MRNS) of a class action securities lawsuit. https://zlk.com/pslra-1/marinus-pharmaceuticals-inc-lawsuit-submission-form?prid=90732&wire=3 WHAT'S NEXT? If you suffered a loss in Marinus during the relevant time frame, you have until August 5, 2024 to request that the Court appoint you as lead plaintiff. Your ability to share in any recovery doesn't requir ...
The Gross Law Firm Reminds Marinus Pharmaceuticals, Inc. Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of August 5, 2024 – MRNS
GlobeNewswire News Room· 2024-07-15 14:51
Core Viewpoint - The Gross Law Firm is notifying shareholders of Marinus Pharmaceuticals, Inc. regarding a class action lawsuit due to alleged misleading statements and omissions related to clinical trial results [1][2]. Group 1: Class Action Details - The class period for the lawsuit is from March 17, 2021, to May 7, 2024 [2]. - Allegations include that Marinus Pharmaceuticals understated the risk of failing to meet early-stopping criteria in the RAISE trial and did not disclose the potential consequences of such failure, which could impact the Phase 3 RAISE II trial [2]. - The lawsuit claims that the defendants' statements about the company's business and prospects were materially false and misleading [2]. Group 2: Shareholder Actions - Shareholders are encouraged to register for the class action by the deadline of August 5, 2024, to potentially become lead plaintiffs [3]. - Once registered, shareholders will receive updates through a portfolio monitoring software regarding the case's progress [3]. - Participation in the case incurs no cost or obligation for the shareholders [3]. Group 3: Law Firm Background - The Gross Law Firm is a nationally recognized class action law firm focused on protecting investors' rights against deceit and fraud [4]. - The firm aims to ensure companies adhere to responsible business practices and seeks recovery for investors who suffered losses due to misleading statements [4].
ROSEN, A LEADING AND RANKED FIRM, Encourages Marinus Pharmaceuticals, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action First Filed by the Firm – MRNS
GlobeNewswire News Room· 2024-07-13 12:41
WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Marinus Pharmaceuticals, Inc. (NASDAQ: MRNS) between March 17, 2021 and May 7, 2024, both dates inclusive (the "Class Period"), of the important August 5, 2024 lead plaintiff deadline in the securities class action first filed by the Firm. WHAT TO DO NEXT: To join the Marinus class action, go to https://rosenlegal.com/submit-form/? case_id=25735 or call Phillip Kim, Esq. toll-free at 866-767-3653 or email case@rosenl ...
Shareholders that lost money on Marinus Pharmaceuticals, Inc.(MRNS) should contact The Gross Law Firm about pending Class Action - MRNS
Prnewswire· 2024-07-12 09:45
Core Viewpoint - Marinus Pharmaceuticals, Inc. is facing a class action lawsuit due to allegations of issuing materially false and misleading statements regarding the risks associated with their clinical trials, particularly the RAISE trial and its implications for the RAISE II trial [2][3]. Group 1: Allegations and Class Period - The class period for the lawsuit is defined as March 17, 2021, to May 7, 2024 [2]. - Allegations include that the defendants understated the risk of failing to meet early-stopping criteria in the RAISE trial and did not disclose the potential consequences of such failure, which could lead to the cessation of the RAISE II trial [2]. Group 2: Shareholder Actions - Shareholders who purchased MRNS shares during the class period are encouraged to register for the class action and can do so without any cost or obligation [3]. - The deadline for shareholders to seek lead plaintiff status is August 5, 2024 [3]. Group 3: Law Firm's Role - The Gross Law Firm is a nationally recognized class action law firm dedicated to protecting investors' rights against deceit and fraud [4]. - The firm aims to recover losses incurred by investors due to misleading statements or omissions that led to artificial inflation of the company's stock [4].
MRNS Investors Have Opportunity to Lead Marinus Pharmaceuticals, Inc. Securities Fraud Lawsuit Filed by The Rosen Law Firm
Prnewswire· 2024-07-11 23:45
NEW YORK, July 11, 2024 /PRNewswire/ -- Why: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Marinus Pharmaceuticals, Inc. (NASDAQ: MRNS) between March 17, 2021 and May 7, 2024, both dates inclusive (the "Class Period"), of the important August 5, 2024 lead plaintiff deadline in the securities class action first filed by the Firm. So what: If you purchased Marinus securities during the Class Period you may be entitled to compensation without payment of any out of pocke ...
Marinus Pharmaceuticals, Inc. Class Action: The Gross Law Firm Reminds Marinus Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of August 5, 2024 – MRNS
GlobeNewswire News Room· 2024-07-09 18:44
NEW YORK, July 09, 2024 (GLOBE NEWSWIRE) -- The Gross Law Firm issues the following notice to shareholders of Marinus Pharmaceuticals, Inc. (NASDAQ: MRNS). CLASS PERIOD: March 17, 2021 to May 7, 2024 CONTACT US HERE: ALLEGATIONS: The complaint alleges that during the class period, Defendants issued materially false and/or misleading statements and/or failed to disclose that: (1) defendants understated the risk of failure to meet the early-stopping criteria in the Randomized Therapy in Status Epilepticus Tri ...